GSK•benzinga•December 20, 2024 at 09:01 AM

GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of Overa

No summary available.

Read the full article from the original source for complete details and context.

Article published on December 20, 2024 by benzinga